Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serpin family G member 1 (SERPING1) encodes C1 inhibitor (C1-INH), a highly glycosylated plasma protein belonging to the serpin superfamily. C1-INH is a critical regulator of the complement system, modulating classical pathway activation by inhibiting proteases such as C1r, C1s, plasma kallikrein, and activated factor XII (factor XIIa). This inhibition limits inflammation, vascular permeability, and edema formation. Mutations in SERPING1 cause hereditary angioedema, characterized by episodic swelling due to uncontrolled bradykinin production. C1-INH is targeted therapeutically in hereditary angioedema and investigated as a biomarker in cardiovascular and inflammatory conditions
Replacement therapy: replenishes functional C1 inhibitor to restore regulation of complement and kallikrein/bradykinin pathways. Inhibition of bradykinin-mediated vascular leakage. Inhibition of plasma kallikrein/factor XIIa activity via irreversible binding ("suicide substrate" mechanism).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serpin family G member 1 (SERPING1).